Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell/Tumor Fusion Vaccine with GM-CSF and Imiquimod in Ovarian Cancer
NCT00799110Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2008
- Primary completion
- Aug 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell-tumor fusion vaccine in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Beth Israel Deaconess Medical Center. Started May 2008; status: terminated.
02
Drugs
autologous dendritic cell-tumor fusion vaccine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00799110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00799110.